{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:56:11Z","timestamp":1782287771151,"version":"3.54.5"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,20]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To update an evidence base informing the 2024 Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis (RA) in older adults.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Four clinical questions (CQs) regarding efficacy and safety of drug treatment were evaluated, with CQ1 addressing methotrexate (MTX), CQ2 biological disease-modifying antirheumatic drugs, CQ3 Janus kinase (JAK) inhibitors, and CQ4 glucocorticoids (GCs). Quality of the evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation system.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Observational studies confirmed a pivotal role of methotrexate in the treatment of older RA patients. The meta-analysis showed that tumour necrosis factor inhibitors and JAK inhibitors were unequivocally effective in older RA patients. No data indicated that biological disease-modifying antirheumatic drugs were unsafe for older patients. No safety data for JAK inhibitor use in older patients were available. One randomized controlled trial demonstrated that long-term treatment with low-dose GCs increased risks of GC-associated adverse events. The certainty of overall evidence was very low for all CQs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This systematic review provides the necessary evidence for developing 2024 Japan College of Rheumatology clinical practice guidelines for managing older patients with RA. Continued updates on the evidence of JAK inhibitors and GC are desired.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roae026","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T14:18:28Z","timestamp":1709561908000},"page":"867-880","source":"Crossref","is-referenced-by-count":9,"title":["Systematic review for the treatment of older rheumatoid arthritis patients informing the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7181-7494","authenticated-orcid":false,"given":"Takahiko","family":"Sugihara","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kawahito","sequence":"additional","affiliation":[{"name":"Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yanai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Showa University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yajima","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Showa University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayo","family":"Kojima","sequence":"additional","affiliation":[{"name":"Nagoya City University, Graduate School of Medical Sciences , Nagoya, Aichi,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"2024101507120540500_R1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/mr\/roac017","article-title":"Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication","volume":"33","author":"Kawahito","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2024101507120540500_R2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14397595.2021.1912922","article-title":"Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis","volume":"32","author":"Sugihara","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2024101507120540500_R3","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2024101507120540500_R4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"2024101507120540500_R5","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1093\/rheumatology\/keaa922","article-title":"Effectiveness and safety of treat-to-target strategy in elderly-onset rheumatoid arthritis: a 3-year prospective observational study","volume":"60","author":"Sugihara","year":"2021","journal-title":"Rheumatology"},{"key":"2024101507120540500_R6","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-022-02952-1","article-title":"Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative","volume":"24","author":"Li","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2024101507120540500_R7","first-page":"234","article-title":"Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis","volume":"33","author":"Bathon","year":"2006","journal-title":"J Rheumatol"},{"key":"2024101507120540500_R8","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1968-x","article-title":"Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged &lt; 65 years and those &gt;\/= 65 years of age","volume":"21","author":"Tesser","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024101507120540500_R9","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-022-02807-9","article-title":"Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study","volume":"24","author":"Sakai","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2024101507120540500_R10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","article-title":"Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology"},{"key":"2024101507120540500_R11","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/mr\/roab058","article-title":"Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2024101507120540500_R12","first-page":"390","article-title":"Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis","volume":"35","author":"Curtis","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2024101507120540500_R13","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000546","article-title":"Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"2024101507120540500_R14","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/annrheumdis-2021-221957","article-title":"Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial","volume":"81","author":"Boers","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024101507120540500_R15","doi-asserted-by":"crossref","first-page":"870","DOI":"10.7326\/M20-1594","article-title":"Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a cohort study","volume":"173","author":"George","year":"2020","journal-title":"Ann Intern Med"},{"key":"2024101507120540500_R16","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/rheumatology\/keab548","article-title":"Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink","volume":"61","author":"Abtahi","year":"2022","journal-title":"Rheumatology"},{"key":"2024101507120540500_R17","first-page":"1285","article-title":"Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis","volume":"18","author":"van der Heijde","year":"1991","journal-title":"J Rheumatol"},{"key":"2024101507120540500_R18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/rheumatology\/ket399","article-title":"Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort","volume":"53","author":"Mueller","year":"2014","journal-title":"Rheumatology"},{"key":"2024101507120540500_R19","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/1756-185X.13428","article-title":"Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort","volume":"22","author":"Murata","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2024101507120540500_R20","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/rheumatology\/keu395","article-title":"Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE)","volume":"54","author":"Sugihara","year":"2015","journal-title":"Rheumatology"},{"key":"2024101507120540500_R21","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2022-eular.1302","article-title":"Associated factors with physical dysfunction of elderly-onset rheumatoid arthritis treated with a treat-to-target strategy","volume":"81","author":"Sugihara","year":"2022","journal-title":"Ann Rheumatic Dis"},{"key":"2024101507120540500_R22","first-page":"460","article-title":"Real world evidence of treatment effectiveness and unfavorable clinical events for elderly-onset early rheumatoid arthritis in Japan: results from the IORRA study","volume":"74","author":"Sugitani","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2024101507120540500_R23","doi-asserted-by":"crossref","DOI":"10.1093\/mr\/roae027","article-title":"Comparison of effectiveness of methotrexate in patients with late-onset versus younger onset rheumatoid arthritis: real-world data from an inception cohort in Japan (NICER-J).","author":"Asai","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2024101507120540500_R24","article-title":"Effectiveness and safety of treat-to-target strategy for methotrexate-na\u00efve rheumatoid arthritis patients &gt;75\u2009years of age","volume":"8","author":"Matsumoto","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"2024101507120540500_R25","first-page":"3960","article-title":"Long-term outcome of a treat-to-target strategy in elderly-onset rheumatoid arthritis with chronic lung diseases","volume":"74","author":"Nomura","year":"2022","journal-title":"Arthritis Rheum"},{"key":"2024101507120540500_R26","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3899\/jrheum.140533","article-title":"Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population","volume":"42","author":"Hashimoto","year":"2015","journal-title":"J Rheumatol"},{"key":"2024101507120540500_R27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/14397595.2021.1899570","article-title":"Clinicopathological characteristics of lymphoproliferative disorders in 232 patients with rheumatoid arthritis in Japan: a retrospective, multicenter, descriptive study","volume":"32","author":"Takada","year":"2022","journal-title":"Mod Rheum"},{"key":"2024101507120540500_R28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/14397595.2020.1869370","article-title":"Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: results from a Japanese multi-institutional retrospective study","volume":"32","author":"Honda","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2024101507120540500_R29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/14397595.2021.1879362","article-title":"Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course: a retrospective, multicenter, case-control study","volume":"32","author":"Kuramoto","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2024101507120540500_R30","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/rheumatology\/kex002","article-title":"Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate","volume":"56","author":"Saito","year":"2017","journal-title":"Rheumatology"},{"key":"2024101507120540500_R31","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152301","article-title":"Comparison between rheumatoid arthritis with malignant lymphoma and other malignancies: analysis of a National Database of Rheumatic Disease in Japan","volume":"63","author":"Mizushima","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2024101507120540500_R32","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s40266-019-00691-8","article-title":"Efficacy and safety of etanercept in elderly patients with rheumatoid arthritis: a post-hoc analysis of randomized controlled trials","volume":"36","author":"Edwards","year":"2019","journal-title":"Drugs Aging"},{"key":"2024101507120540500_R33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40266-019-00721-5","article-title":"An analysis of real-world data on the safety of etanercept in older patients with rheumatoid arthritis","volume":"37","author":"Edwards","year":"2020","journal-title":"Drugs Aging"},{"key":"2024101507120540500_R34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/annrheumdis-2020-218992","article-title":"Age-based (&lt;65 vs &gt;\/=65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry","volume":"80","author":"Winthrop","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024101507120540500_R35","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2024101507120540500_R36","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/art.40911","article-title":"Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"71","author":"Charles-Schoeman","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024101507120540500_R37","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024101507120540500_R38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024101507120540500_R39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/mr\/road098","article-title":"Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: secondary publication","volume":"34","author":"Kameda","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2024101507120540500_R40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024101507120540500_R41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024101507120540500_R42","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1056\/NEJMc070728","article-title":"Pneumocystis pneumonia associated with infliximab in Japan","volume":"357","author":"Harigai","year":"2007","journal-title":"N Engl J Med"},{"key":"2024101507120540500_R43","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/rheumatology\/keab647","article-title":"Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b\/tsDMARDs: insights from 3787 cases in the FIRST registry","volume":"61","author":"Sonomoto","year":"2022","journal-title":"Rheumatology"},{"key":"2024101507120540500_R44","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1136\/ard.2005.047274","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan","volume":"65","author":"Yamada","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2024101507120540500_R45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000354791","article-title":"Serodiagnosis of Mycobacterium avium complex pulmonary disease in rheumatoid arthritis","volume":"87","author":"Komazaki","year":"2014","journal-title":"Respiration"},{"key":"2024101507120540500_R46","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0787-y","article-title":"Diagnostic performance of measuring antibodies to the glycopeptidolipid core antigen specific to Mycobacterium avium complex in patients with rheumatoid arthritis: results from a cross-sectional observational study","volume":"17","author":"Hirose","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2024101507120540500_R47","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3899\/jrheum.180427","article-title":"Associations between methotrexate use and the risk of cardiovascular events in patients with elderly-onset rheumatoid arthritis","volume":"46","author":"Widdifield","year":"2019","journal-title":"J Rheumatol"},{"key":"2024101507120540500_R48","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3899\/jrheum.130365","article-title":"Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study","volume":"40","author":"Ajeganova","year":"2013","journal-title":"J Rheumatol"},{"key":"2024101507120540500_R49","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/1756-185X.13974","article-title":"Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan","volume":"23","author":"Nakajima","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"2024101507120540500_R50","doi-asserted-by":"crossref","DOI":"10.1093\/mr\/roae006","article-title":"Trends in treatment for patients with late-onset rheumatoid arthritis in Japan: data from the NinJa study","author":"Matsui","year":"2024","journal-title":"Mod Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roae026\/57039168\/roae026.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/5\/867\/59755435\/roae026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/5\/867\/59755435\/roae026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T07:13:31Z","timestamp":1728976411000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/5\/867\/7623078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3,6]]},"published-print":{"date-parts":[[2024,8,20]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roae026","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,3,6]]}}}